Autoantibodies and other serological markers in rheumatoid arthritis: Predictors of disease activity?

Clinical Rheumatology

Volumn 28, Issue 10, 2009, Pages 1127-1134

  da Mota, Licia Maria Henrique ^a   dos Santos Neto, Leopoldo Luiz ^a   de Carvalho, Jozélio Freire ^b  

^a HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoantibodies; Disease activity; Rheumatoid arthritis; Serological markers

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; AUTOANTIBODY; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CITRULLINE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 9; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FILAGGRIN; GLYCOPROTEIN GP 39; GLYCOSAMINOGLYCAN; GOLD SALT; HYALURONIC ACID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; INTERLEUKIN 6; LEPTIN; MANNOSE BINDING LECTIN; MATRIX METALLOPROTEINASE; MUTATED CITRULLINATED VIMENTIN ANTIBODY; OSTEOCALCIN; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

BONE METABOLISM; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JOINT EXAMINATION; LABORATORY DIAGNOSIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; VISUAL ANALOG SCALE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 69949182843     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1223-y     Document Type: Review

References (68)

1. Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH (2005) Development and assessment of indicators of rheumatoid arthritis severity: Results of a Delphi panel. Arthritis Rheum 53:61-66
2. Khanna D, Oh M, Furst DE et al (2007) Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 15(57):440-447
3. Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 66:216-223
4. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB (1982) Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 19:224-228
5. Ringold S, Singer NG (2008) Measures of disease activity in rheumatoid arthritis: A clinician's guide. Curr Rheum Rev 4:259-265
6. Prevoo MLL, Van'T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
7. Smolen JS, Breedveld FC, Schiff MH et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244-257
8. Aletaha D, Nell VP, Stamm T et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796-R806
9. Devlin J (1997) The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 24:9-13
10. Keenan RT, Swearingen CJ, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26:814-819
11. Renaudineau Y, Jamin C, Saraux A, Youinou P (2005) Rheumatoid factor on a daily basis. Autoimmunity 38:11-16
12. Vittecoq O, Pouplin S, Krzanowska K et al (2003) Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 42:939-946
13. Visser H (2005) Early diagnosis of rheumatoid arthritis. Best Pract & Res Clin Rheum 19:55-72
14. Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157-161
15. Wolfe F, Cathey MA, Roberts FK (1991) The latex test revised rheumatoid factor testing in 8287 rheumatic disease patients. Arthritis Rheum 34:951-960
16. Swedler W, Wallman J, Froelich CJ, Teodorescu M (1997) Routine measurement of IgM, IgG, and IgA rheumatoid factors: High sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 24:1037-1044
17. Lemm G, Ruschen S, Warnatz H (1988) An ELISA for IgA-IgG and IgM-RF measurement II. RF in several disease and control groups and under gold therapy in RA. Scand J Rheumatol Suppl 75:256-260
18. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:R264-R272
19. Bobbio-Pallavicini F, Caporali R, Alpini C et al (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66:302-307
20. Bos WH, Bartelds GM, Wolbink GJ et al (2008) Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 35:1972-1977
21. Ates A, Kinikli G, Turgay M, Akay G, Tokgöz G (2007) Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: A comparative study. Clin Rheumatol 26:538-545
22. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079-1084
23. Greiner A, Plischke H, Kellner H, Gruber R (2005) Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 1050:295-303
24. Raza K, Breese M, Nightingale P et al (2005) Predictive value of antibodies to cyclic citrullinated peptides in patients with very early inflammatory arthritis. J Rheumatol 32:231-238
25. Solbritt RD, Ben AWJ, Berglin E, Hallmans G et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749
26. Svärd A, Kastbom A, Reckner-Olsson A, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: The Swedish TIRA project. Arthritis Res Ther 10:R75
27. Serdaroglu M, Cakirbay H, Defer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965-970
28. Mathson L, Mullazei M, Wick MC et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36-45
29. Ursum J, Nielen MMJ, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: A cohort study. Arthritis Res Ther 10:R12
30. Innala L, Kokkonen H, Ericsson C, Jidell E, Berglin E, Rantapää-Dahlqvist S (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 5:1002-1008
31. Ursum J, Nielen MMJ, Schaardenburg DV, van der Horst AR, van de Stadt RJ, Dijkmans BA (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: A cohort study. Arthritis Res Ther 10:1-6
32. Cordonnier C, Meyer O, Palazzo E, De Bandt M, Elias A, Nicaise P et al (1996) Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: Comparison with rheumatoid factor. Br J Rheumatol 35:620-624
33. Vittecoq O, Incaurgarat B, Jouen-Beades F et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Rheumatol 135:173-180
34. Nielen MM, van der Horst AR, van Schaardenburg D et al (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199-1204
35. Graudal N, Svenson M, Tarp U, Garred P, Jurik A, Bendtzen K (2002) Autoantibodies against interleukin-1 alfa in rheumatoid arthritis: association with long-term radiographic outcome. Ann Rheum Dis 61:598-602
36. Saulot V, Vittecoq O, Charlionet R et al (2002) Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 46:1196-1201
37. Newkirk MM, Goldbach-Mansky R, Lee J et al (2003) Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 5:R82-90
38. Garnero P, Delmas PD (2004) Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: Bone biomarkers. Curr Opin Rheumatol 16:428-434
39. Mohammed F, Smookler D, Khokha R (2003) Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 62:43-47
40. Jensen T, Klarlund M, Hansen M (2004) Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density and radiographic outcomes. J Rheumatol 31:1698-1708
41. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2000) Serum matrix metalloproteinase 3 in with early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 27:2761-2768
42. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2003) Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol 21:465-472
43. Green MJ, Gough AKS, Devlin J, Smith J, Astin P, Taylor D (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 42:83-88
44. Majeed M, McQueen F, Yeoman S, McLean L (2004) Relationship between serum hyaluronic acid level and disease activity in early rheumatoid arthritis. Ann Rheum Dis 63:1166-1168
45. Garnero P, Landewé R, Boers M et al (2002) Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: The COBRA study. Arthritis Rheum 46:2847-2856
46. Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J (2004) Markers for type II collagen breakdown predict the effect of disease modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 50:1390-1399
47. Landewé RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, Garnero P (2006) Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: A longitudinal analysis. Ann Rheum Dis 65:40-44
48. Charni N, Juillet F, Garnero P (2005) Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 52:1081-1090
49. Jansen LMA, van der Horst-Bruinsma IE, Lems WF (2004) Serological bone markers and joint damage in early polyarthritis. J Rheumatol 31:1491-1496
50. Forslind K, Eberhardt K, Jonsson A, Saxne T (1992) Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 31:593-598
51. Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T (2004) Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: Relation to diagnosis and disease activity. Scand J Rheumatol 33:185-188
52. Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T (2003) Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5:R181-R185
53. György B, Tóthfalusi L, Nagy G et al (2008) Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. Arthritis Res Ther 10:R110
54. Morgante M, Di Munno O, Morgante D (1999) YKL 40: Marker of disease activity in rheumatoid arthritis? Minerva Med 90:437-441
55. Johansen JS, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: Relation to disease activity. Rheumatology (Oxford) 38:618-626
56. Matsumoto T, Tsurumoto T (2001) Serum YKL-40 levels in rheumatoid arthritis: Correlations between clinical and laboratory parameters. Clin Exp Rheumatol 19:655-660
57. Jäälinoja J, Nissilä M, Kauppi MJ et al (2008) Serum antibodies against intact human collagen IX are elevated at onset of rheumatoid arthritis but are not related to development of erosions. J Rheumatol 35:745-751
58. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Hl V (2001) Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. J Rheum 28:728-734
59. Grauldal N (2004) The natural history and prognosis of rheumatoid arthritis: Association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol Suppl 118:1-38
60. Kuuliala A, Eberhardt K, Takala A, Kautiainen H, Repo H, Leirisalo-Repo M (2002) Circulating soluble E-selectin in early rheumatoid arthritis: A prospective five year study. Ann Rheum Dis 61:242-246
61. Corona-Sanchez EG, Gonzalez-Lopez L, Muñoz-Valle JF et al (2009) Circulating E-selectin and tumor necrosis factor-alpha in extraarticular involvement and joint disease activity in rheumatoid arthritis. Rheumatol Int 29:281-286
62. Klimiuk PA, Sierakowski S, Domysławska I, Fiedorczyk M, Chwiećko J (2004) Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 52:36-42
63. Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N (1995) Serum Interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol 1:93-98
64. Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232-234
65. Targońska-Stepniak B, Majdan M, Dryglewska M (2008) Leptin serum levels in rheumatoid arthritis patients: Relation to disease duration and activity. Rheumatol Int 28:585-591
66. Seven A, Güzel S, Aslan M, Hamuryudan V (2009) Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int 29(7):743-747
67. Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 99:1078-1083
68. Hizmetli S, Kisa M, Gokalp N, Bakici MZ (2007) Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int 27:335-338